Sernova (PSH0) Price & Analysis

Compare

2 Followers

PSH0 Stock Chart & Stats

€0.11

Market closed

€0.11

Day’s Range― - ―

52-Week Range€0.06 - €0.20

Previous CloseN/A

VolumeN/A

Average Volume (3M)4.46K

Market Cap

€30.21M

Enterprise Value€65.84M

Total Cash (Recent Filing)€265.00K

Total Debt (Recent Filing)€17.28M

Price to Earnings (P/E)―

Beta0.26

Next Earnings

Mar 19, 2026

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding336,698,550

10 Day Avg. Volume5,531

30 Day Avg. Volume4,462

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)-1.96

Price to Sales (P/S)0.00

P/FCF Ratio-4.51

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Cell Pouch TechnologySernova’s Cell Pouch System is a platform implantable device creating a vascularized pocket for therapeutic cells, giving the company a durable, platform-level competitive angle in cell-based therapies for chronic diseases like diabetes. Platform orientation supports multiple indications and long-term strategic optionality around licensing or partnering once clinical efficacy is proven.

Meaningful Reduction In Operating LossesThe company has materially reduced operating cash burn and net losses over two years, reflecting tighter cost control or program prioritization. Sustained downward trend in burn increases the likelihood management can extend runway from existing capital or smaller financings, improving the odds of executing near-term clinical milestones without as large periodic dilution events.

Recent Financing And Debt-to-equity ConversionThe CAD ~$13.3M debt-to-equity conversion and additional financings materially reduce immediate cash-flow obligations and improve liquidity structure. Structurally this lowers near-term refinancing pressure, supports continuation of clinical programs, and makes future partner discussions or milestone-driven funding more viable versus pre-conversion debt burden.

Bears Say

Pre-revenue Development ProfileSernova remains pre-revenue, meaning it lacks product-derived cash flow and must fund operations via capital markets or partners. Over a multi-month horizon this structurally elevates financing and execution risk: until commercial sales or licensing occur, the business depends on external funding, which can dilute shareholders and constrain long-term planning.

Deteriorated Balance Sheet And Negative EquityThe shift to materially negative equity, higher debt and very low reported assets signals weakened financial resilience. Structurally this restricts borrowing capacity, raises refinancing and covenant risk, and increases the likelihood of future dilutive financings or asset sales to fund trials, which can impede steady clinical development and strategic independence.

Persistent Negative Free Cash FlowDespite burn improvement, free cash flow remains negative and worsened year-over-year, indicating structural inability to self-fund. Over the next several months this necessitates continued external financing or partnerships, raising dilution risk and potentially forcing prioritization of programs, which could delay development timelines and reduce optionality.

Sernova News

Sernova Biotherapeutics Advances Diabetes Treatment with New Funding

Sernova ( ($TSE:SVA) ) has shared an announcement. Sernova Biotherapeutics has successfully closed the first tranche of a...

3M ago

Sernova Biotherapeutics Strengthens Financial Position with Debt-to-Equity Conversion

Sernova ( ($TSE:SVA) ) has provided an announcement. Sernova Biotherapeutics announced a significant financial restructuring by converting approximately...

5M ago

Sernova Biotherapeutics Appoints John L. Brooks III as Board Chair to Advance Diabetes Cure

The latest announcement is out from Sernova ( ($TSE:SVA) ). Sernova Biotherapeutics has appointed John L. Brooks III...

5M ago

Sernova Biotherapeutics to Present at Global Investment Conference

Sernova ( ($TSE:SVA) ) has issued an update. Sernova Biotherapeutics announced its participation in the H.C. Wainwright 27th...

5M ago

Sernova and Eledon Collaborate on Potential Type 1 Diabetes Cure

The latest update is out from Sernova ( ($TSE:SVA) ). Sernova Biotherapeutics has announced a collaboration with Eledon...

7M ago

Promising Advancements and Strategic Partnerships Bolster Sernova’s Buy Rating for T1D Treatment

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sernova today and set a price target of...

7M ago

Sernova’s Promising T1D Treatment Strategy Gains Confidence with External Validation and Unique Cell Pouch System

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sernova (SVA – Research Report) today and set...

8M ago

Sernova Biotherapeutics Appoints Interim Chair Amid Strategic Advancements

Sernova ( ($TSE:SVA) ) has shared an announcement. Sernova Biotherapeutics has appointed its CEO, Jonathan Rigby, as the...

9M ago

Sernova Biotherapeutics Forms Clinical Advisory Board to Advance Diabetes Treatment

Sernova ( ($TSE:SVA) ) just unveiled an announcement. Sernova Biotherapeutics has announced the formation of a Clinical Advisory...

9M ago

Sernova’s Cell Pouch Shows Promising Results in Diabetes Trial

Sernova ( ($TSE:SVA) ) has provided an update. Sernova Biotherapeutics announced positive interim data from its ongoing Phase...

9M ago

PSH0 FAQ

What was Sernova Corp’s price range in the past 12 months?

Sernova Corp lowest stock price was €0.06 and its highest was €0.20 in the past 12 months.

What is Sernova Corp’s market cap?

Sernova Corp’s market cap is €30.21M.

When is Sernova Corp’s upcoming earnings report date?

Sernova Corp’s upcoming earnings report date is Mar 19, 2026 which is in 30 days.

How were Sernova Corp’s earnings last quarter?

Sernova Corp released its earnings results on Dec 19, 2025. The company reported -€0.003 earnings per share for the quarter, beating the consensus estimate of -€0.006 by €0.003.

Is Sernova Corp overvalued?

According to Wall Street analysts Sernova Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sernova Corp pay dividends?

Sernova Corp does not currently pay dividends.

What is Sernova Corp’s EPS estimate?

Sernova Corp’s EPS estimate is >-0.01.

How many shares outstanding does Sernova Corp have?

Sernova Corp has 336,698,550 shares outstanding.

What happened to Sernova Corp’s price movement after its last earnings report?

Sernova Corp reported an EPS of -€0.003 in its last earnings report, beating expectations of -€0.006. Following the earnings report the stock price went up 24.39%.

Which hedge fund is a major shareholder of Sernova Corp?

Currently, no hedge funds are holding shares in DE:PSH0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sernova Corp

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.